Financial Performance - The Group's revenue for the financial period amounted to approximately HK$3.2 million, representing an increase of approximately 5.8% compared to HK$3.0 million in the previous financial period[11]. - The Group recorded a loss attributable to the owners of the Company of approximately HK$116.1 million, compared to a profit of HK$101.7 million in the previous financial period[11]. - Revenue from the trading of beauty and health products was approximately HK$3.2 million, reflecting a 5.8% increase from the previous financial period[12]. - For the six months ended September 30, 2025, the company reported revenue of HK$3,206,000, an increase from HK$3,029,000 in the same period of 2024, representing a growth of approximately 5.85%[85]. - The gross profit for the period was HK$447,000, compared to HK$307,000 in the previous year, indicating a significant increase of 45.6%[85]. - The company incurred a loss before tax of HK$119,304,000, a decline from a profit of HK$100,966,000 in the same period last year[85]. - The total comprehensive income for the period was a loss of HK$119,246,000, compared to a profit of HK$100,994,000 in the previous year[85]. - For the six months ended September 30, 2025, the consolidated loss for the period was HK$119,304,000, compared to a profit of HK$100,966,000 for the same period in 2024[128]. Research and Development - The Group launched its health supplement product "Pancreon PRO" in September 2025, aimed at insulin health and blood sugar management[12]. - The in-process research and development project for an oral insulin product has a net carrying value of HK$1,076 million recorded as an intangible asset[14]. - Approximately 405 patients have been enrolled in the clinical trial testing for the oral insulin product, which commenced in July 2020[20]. - The oral insulin product is expected to be launched in the market by the third quarter of 2028, with significant demand anticipated due to the growing diabetic population in China[21]. - The product is expected to be the first oral insulin drug available in the market and will be protected for a period of 5 years under current regulations in China[21]. - The Group plans to inject additional resources into the clinical trial of the in-process R&D to facilitate its development[13]. - The Group has entered into a Preliminary Partnership Agreement with Johns Hopkins University School of Medicine to collaborate on research related to diabetes and cardiovascular disease[27]. - The Group's core mission is to provide reliable health supplement solutions for the diabetic population, with several insulin-related health products planned for launch in Hong Kong[25]. Financial Position - As of September 30, 2025, the Group's bank and cash balances were approximately HK$18.1 million, up from HK$3.7 million as of March 31, 2025[38]. - Total borrowings as of September 30, 2025, were approximately HK$1,143.0 million, an increase from HK$1,049.2 million as of March 31, 2025[39]. - As of September 30, 2025, the Group's current assets to current liabilities ratio was 0.02, up from 0.01 as of March 31, 2025[42]. - The Group's gearing ratio increased to 1.07 as of September 30, 2025, compared to 0.98 as of March 31, 2025, with total liabilities of approximately HK$1,191.1 million and total assets of approximately HK$1,110.7 million[42]. - The Group's cash and cash equivalents at the end of the period amounted to approximately HK$18,071,000, with a net increase of HK$14,404,000 during the six months[98]. - The Group's bank balances and cash are significantly lower than the liabilities due, indicating potential liquidity issues[105]. - The Group's major asset, the development of an oral insulin product, is currently in Phase III clinical trials, with future cash flow dependent on successful trial outcomes and regulatory approvals[105]. Staff and Administrative Expenses - The total staff costs, including Directors' remuneration, for the Financial Period amounted to approximately HK$3.6 million, an increase from approximately HK$2.9 million in the previous Financial Period[53]. - As of September 30, 2025, the Group had 29 full-time employees, an increase from 20 as of March 31, 2025[52]. - Administrative expenses rose to HK$12,386,000 from HK$6,683,000, reflecting an increase of 85.5% year-over-year[85]. - Total short-term employment benefits for key management personnel were HK$1,874,000 for the six months ended September 30, 2025, an increase from HK$1,754,000 in the prior year[185]. Financing and Capital Structure - The Company completed the placing of 23,555,000 shares at a price of HK$0.175 per share, generating gross proceeds of approximately HK$4,122,000, with net proceeds of approximately HK$4,000,000 fully utilized for general working capital[44]. - The company issued convertible bonds worth HK$48,212,000 during the period, contributing to changes in equity[94]. - The Company is in the final stages of negotiating the extension and restructuring of Convertible Bonds due on 28 July 2025, which is expected to alleviate short-term debt pressure[110]. - The company recognized new Convertible Bonds I after substantial modification, with a liability component of approximately HK$31,709,000 and an equity component of HK$281,320,000[156]. - The maturity date of Convertible Bonds III has been extended to July 28, 2025, as per the third amendment agreed with Extrawell[169]. Risk Management and Future Outlook - The Group maintained a prudent strategy in foreign exchange risk management, balancing foreign currency assets against liabilities without using financial instruments for hedging during the Financial Period[51]. - The Company has not established a dividend policy, considering it more appropriate to determine dividend payments based on financial performance and market conditions[61]. - Significant uncertainties exist regarding the successful implementation of the Company's plans, particularly the completion of the Clinical Trial and product launch[113]. - The financial statements have been prepared on a going concern basis, assuming the Group can meet its financial obligations in the next 12 months[106]. - The Company received financial support from a substantial shareholder, confirming that repayment of approximately HK$8,190,000 will not be demanded for at least 12 months from the date of the financial statements[108].
星太链集团(00399) - 2026 - 中期财报